Sloan Sheldon (CIK 2038798) reported 15 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Buy SYRE (8,334 shares), Sell SYRE (6,500 shares), Sell SYRE (1,834 shares), Buy SYRE (8,333 shares), Sell SYRE (8,333 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Buy | 8,334 | $228,852 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 6,500 | $568,880 |
| 2026-07-02 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 1,834 | $162,016 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Buy | 8,333 | $228,824 |
| 2026-06-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 8,333 | $624,975 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Buy | 78,333 | $2.2M |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 21,306 | $1.5M |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 19,656 | $1.4M |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 8,777 | $628,082 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 12,777 | $931,954 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 10,358 | $763,799 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 5,059 | $377,401 |
| 2026-05-01 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 400 | $30,148 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Buy | 7,958 | $172,370 |
| 2026-04-03 | Spyre Therapeutics, Inc. (SYRE) | Chief Medical Officer | Sell | 7,958 | $397,900 |
Source: SEC Form 4 filings · as of 2026-07-02